{
    "Clinical Trial ID": "NCT00834678",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Bendamustine and Erlotinib",
        "  Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.",
        "  Participants in dose level II were administered 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed breast cancer meeting 1 of the following criteria:",
        "  Unresectable stage IIIB or IIIC disease",
        "  Stage IV disease",
        "  Must be negative for all of the following:",
        "  Estrogen receptor (< 10%)",
        "  Progesterone receptor (<10%)",
        "  HER-2 (negative FISH, IHC 0 - 1+, or IHC +2 with negative FISH)",
        "  Measurable or evaluable disease",
        "  No symptomatic or progressive CNS (central nervous system) metastases",
        "  Previously treated CNS metastases allowed provided all of the following criteria are met:",
        "  At least 8 weeks since prior radiation to brain or CNS metastases",
        "  No concurrent steroids",
        "  No leptomeningeal disease",
        "  PATIENT CHARACTERISTICS:",
        "  Menopausal status not specified",
        "  ECOG (Eastern Cooperative Oncology Group) performance status 0-2",
        "  Life expectancy  6 months",
        "  WBC > 1,500/mm\u00b3",
        "  Platelet count > 100,000/mm\u00b3",
        "  Creatinine clearance > 40 mL/min",
        "  Normal electrolytes (i.e., Na, K, and Ca normal; minor deviations are allowed if they do not impact on patient safety in the clinical judgment of the treating physician)",
        "  Bilirubin  1.5 times upper limit of normal (ULN)",
        "  ALT and AST  2.5 times ULN ( 5 times ULN in the presence of documented liver metastases)",
        "  Alkaline phosphatase  2.5 times ULN ( 5 times ULN in the presence of liver or bone metastases)",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective barrier contraception",
        "  No uncontrolled intercurrent illness",
        "  No active infection requiring systemic therapy",
        "  Able to swallow oral medications and with no medical problems or prior surgeries that may interfere with the absorption of oral medications including the following:",
        "  Uncontrolled nausea, vomiting, or diarrhea",
        "  Lack of the physical integrity of the upper gastrointestinal tract",
        "  Malabsorption syndrome",
        "  No known hypersensitivity to bendamustine hydrochloride, mannitol, or erlotinib hydrochloride",
        "  No prior malignancy in the past 5 years except for adequately treated basal cell or squamous cell skin carcinoma, or adequately treated stage I-II cancer for which the patient is in complete remission",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  Prior adjuvant or neoadjuvant chemotherapy and 1 prior chemotherapy regimen in the metastatic setting allowed provided recovered from all acute toxicities",
        "  No prior bendamustine hydrochloride or EGFR-directed therapy",
        "  No other concurrent antineoplastic treatments, including radiotherapy, chemotherapy, biological therapy, hormonal therapy, immunotherapy, gene therapy, and surgery",
        "  Intravenous bisphosphonates allowed",
        "  No concurrent antiretroviral therapy for HIV-positive patients",
        "  No other concurrent investigational agents"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)",
        "  28 day cycle included intravenous bendamustine on days 1 and 2.",
        "  Time frame: Up to two years",
        "Results 1: ",
        "  Arm/Group Title: Bendamustine and Erlotinib",
        "  Arm/Group Description: Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.",
        "  Participants in dose level II were administered 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.",
        "  Overall Number of Participants Analyzed: 11",
        "  Measure Type: Number",
        "  Unit of Measure: mg/m^2  120"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 3/11 (27.27%)",
        "  Infection 3/11 (27.27%)"
    ]
}